Y.D. More Investments Ltd Sells 98,313 Shares of InMode Ltd. (NASDAQ:INMD)

Y.D. More Investments Ltd cut its holdings in shares of InMode Ltd. (NASDAQ:INMD) by 34.1% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 190,051 shares of the healthcare company’s stock after selling 98,313 shares during the quarter. Y.D. More Investments Ltd owned 0.23% of InMode worth $4,227,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Meitav Investment House Ltd. grew its position in InMode by 22.1% during the fourth quarter. Meitav Investment House Ltd. now owns 1,940,890 shares of the healthcare company’s stock worth $43,166,000 after buying an additional 351,863 shares in the last quarter. LSV Asset Management lifted its position in shares of InMode by 3,557.6% during the 3rd quarter. LSV Asset Management now owns 1,678,819 shares of the healthcare company’s stock valued at $51,137,000 after acquiring an additional 1,632,919 shares during the period. Boston Trust Walden Corp acquired a new stake in shares of InMode during the 4th quarter worth $32,366,000. DDD Partners LLC increased its position in shares of InMode by 24.4% in the fourth quarter. DDD Partners LLC now owns 1,228,162 shares of the healthcare company’s stock worth $27,314,000 after purchasing an additional 240,856 shares during the period. Finally, Clal Insurance Enterprises Holdings Ltd raised its stake in InMode by 44.0% in the third quarter. Clal Insurance Enterprises Holdings Ltd now owns 1,080,000 shares of the healthcare company’s stock valued at $32,897,000 after purchasing an additional 330,000 shares in the last quarter. 68.04% of the stock is currently owned by institutional investors and hedge funds.

InMode Trading Up 0.3 %

NASDAQ:INMD traded up $0.05 during trading hours on Wednesday, hitting $17.24. 1,564,600 shares of the company were exchanged, compared to its average volume of 1,554,737. The company has a fifty day simple moving average of $20.13 and a 200 day simple moving average of $21.43. InMode Ltd. has a one year low of $16.82 and a one year high of $48.25. The stock has a market capitalization of $1.45 billion, a price-to-earnings ratio of 7.42 and a beta of 2.16.

InMode (NASDAQ:INMD) last posted its quarterly earnings data on Tuesday, February 13th. The healthcare company reported $0.71 EPS for the quarter, topping analysts’ consensus estimates of $0.66 by $0.05. The company had revenue of $126.80 million for the quarter, compared to analyst estimates of $124.77 million. InMode had a return on equity of 29.80% and a net margin of 40.22%. The firm’s quarterly revenue was down 5.1% on a year-over-year basis. During the same period in the previous year, the firm earned $0.69 earnings per share. Equities research analysts predict that InMode Ltd. will post 2.04 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

INMD has been the topic of several recent analyst reports. UBS Group raised their target price on shares of InMode from $24.00 to $26.00 and gave the company a “neutral” rating in a report on Wednesday, February 14th. Needham & Company LLC reissued a “hold” rating on shares of InMode in a research note on Tuesday, April 9th. Finally, Barclays lowered their price objective on shares of InMode from $34.00 to $33.00 and set an “overweight” rating for the company in a research report on Friday, April 12th. Four analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $32.80.

InMode Company Profile

InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures.